Connect Sign In
ARUP’s chief medical officer urged the House Committee on Ways and Means to consider oversight structures that both protect the public health and support innovation in healthcare.
ARUP Laboratories has been chosen as the site for a House Ways and Means Committee Field Hearing on July 12. Topics include medical innovation, healthcare access, and economic prosperity.
Karen Brisendine, a technologist in Mycology AFB, started working at ARUP in 1984 at the company’s founding. In the past 40 years, she has explored many positions, interests, and ARUP departments.
ARUP’s mission to continually improve patient care will carry the company into the future and drive further advancement of groundbreaking technologies and innovative solutions.
ARUP experts will present at ASM Microbe 2024 on emerging topics in infectious disease, including parasitology, mycobacterial infections, and more.
ARUP Payroll Specialist Heather Oliver’s daughter Kara was diagnosed with Ewing sarcoma in late 2023. By sharing Kara’s story, Oliver hopes to inspire others to donate blood.
ARUP Files Declaration to Support Lawsuit Challenging the FDA's Rule to Regulate Lab-Developed Tests
ARUP’s declaration amplifies the lawsuit’s claims that the FDA does not have legal authority over laboratory testing services and that regulating these services is unreasonable.
ARUP Laboratories is committed to helping clients and the clinical laboratory community navigate regulatory changes and is offering current resources and a new webinar.
ARUP Healthcare Advisory Services Manager David Shiembob has received the ADLM Clinical Laboratory Scientist Achievement Award, which recognizes significant contributions to the CLS community.
The inaugural event created connections among future innovators who look to solve many of healthcare’s biggest challenges.
This issue highlights milestones in ARUP’s history, gives a glimpse into the company’s future, and includes a special feature: a video of ARUP founders and current leaders reminiscing and celebrating.
ARUP maintains that the FDA’s rule will limit access to testing, stifle innovation, and increase healthcare costs.
